M. Basu

发表

IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.

R. Ward, J. Clements, M. McNeal, 2007, Viral immunology.

Functional Mapping of Protective Domains and Epitopes in the Rotavirus VP6 Protein

R. Ward, J. Clements, M. McNeal, 2000, Journal of Virology.

Role of natriuretic peptides in cGMP production in fetal cardiac bypass.

P. Eghtesady, M. Basu, R. Baker, 2009, The Annals of thoracic surgery.

Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.

A. Ramne, R. Ward, J. Bean, 2007, Vaccine.

Identification of an immunodominant CD4+ T cell epitope in the VP6 protein of rotavirus following intranasal immunization of BALB/c mice.

R. Ward, J. Bean, J. Clements, 2007, Virology.

Mice Develop Effective but Delayed Protective Immune Responses When Immunized as Neonates either Intranasally with Nonliving VP6/LT(R192G) or Orally with Live Rhesus Rotavirus Vaccine Candidates

R. Ward, J. Bean, J. Clements, 2006, Journal of Virology.

Antibody-Independent Protection against Rotavirus Infection of Mice Stimulated by Intranasal Immunization with Chimeric VP4 or VP6 Protein

R. Ward, J. Clements, M. McNeal, 1999, Journal of Virology.

Association of Gamma Interferon and Interleukin-17 Production in Intestinal CD4+ T Cells with Protection against Rotavirus Shedding in Mice Intranasally Immunized with VP6 and the Adjuvant LT(R192G)

R. Ward, J. Clements, M. McNeal, 2007, Journal of Virology.

Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.

R. Ward, J. Bean, J. Clements, 2006, Virology.

Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.

R. Ward, J. Bean, J. Clements, 2002, Vaccine.

Development of a Rotavirus-Shedding Model in Rhesus Macaques, Using a Homologous Wild-Type Rotavirus of a New P Genotype

R. Ward, M. McNeal, M. Basu, 2005, Journal of Virology.

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

A. Chen, D. Reinke, B. V. Van Tine, 2020, Sarcoma.

A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low‐grade glioma

S. Prabhu, S. Hunger, C. Herzog, 2020, Pediatric blood & cancer.

Intranasal administration of an Escherichia coli-expressed codon-optimized rotavirus VP6 protein induces protection in mice.

R. Ward, J. Bean, J. Clements, 2004, Protein expression and purification.

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

R. Ward, J. Bean, N. Lycke, 2002, Vaccine.

Particle-bombardment-mediated DNA vaccination with rotavirus VP4 or VP7 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.

R. Ward, M. McNeal, M. Basu, 1998, Virology.

Discovery of a new strain of murine rotavirus that is consistently shed in large quantities after oral inoculation of adult mice.

R. Ward, M. McNeal, M. Basu, 2004, Virology.

Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection.

R. Ward, J. Bean, J. Clements, 2007, Vaccine.

Induction of immune responses and partial protection in mice after skin immunization with rotavirus VP6 protein and the adjuvant LT(R192G).

M. Basu, A. Choi, K. Smiley, 2005, Vaccine.